This company listing is no longer active
ACST Stock Overview
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Acasti Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.58 |
| 52 Week High | CA$1.66 |
| 52 Week Low | CA$0.47 |
| Beta | 1.22 |
| 1 Month Change | -27.50% |
| 3 Month Change | -17.14% |
| 1 Year Change | -62.82% |
| 3 Year Change | -83.89% |
| 5 Year Change | -94.86% |
| Change since IPO | -98.87% |
Recent News & Updates
Shareholder Returns
| ACST | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -6.5% | -1.8% | -0.6% |
| 1Y | -62.8% | 50.8% | 3.9% |
Return vs Industry: ACST exceeded the Canadian Pharmaceuticals industry which returned -65.4% over the past year.
Return vs Market: ACST underperformed the Canadian Market which returned -11.9% over the past year.
Price Volatility
| ACST volatility | |
|---|---|
| ACST Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: ACST's share price has been volatile over the past 3 months.
Volatility Over Time: ACST's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Jan D'Alvise | www.acastipharma.com |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Acasti Pharma Inc. Fundamentals Summary
| ACST fundamental statistics | |
|---|---|
| Market cap | CA$19.23m |
| Earnings (TTM) | -CA$23.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs ACST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.25m |
| Earnings | -US$17.25m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACST perform over the long term?
See historical performance and comparison